Pascal Behr (Cytosurge AG)

Behr, Pascal (Cytosurge 201806 CEO)

	Organisation	Cytosurge AG
	Product	FluidFM® technology
	Product 2	FluidFM® BOT

Cytosurge AG. (6/29/18). "Press Release: Partnership between Bruker and Cytosurge – Enabling FluidFM Single Cell Experiments on the BioScope Resolve BioAFM". Zurich / Glattbrugg.

Cytosurge AG, a Swiss company that develops, manufactures and distributes scientific high-precision nanotechnology instruments and robotic systems based on its patented FluidFM® technology, and Bruker Corporation, one of the world's leading analytical instrumentation companies, have entered into a new partnership. Thanks to this Premium partnership, researchers can combine the femtoliters scale fluid control and cell treatment precision of FluidFM with the force control, resolution and speed available with Bruker’s exclusive PeakForce Tapping® technology.

Due to the new combination with Cytosurge’s FluidFM technology, the BioScope Resolve® BioAFM now becomes an even more powerful tool. The exclusive PeakForce QNM® and FastForce Volume™ capabilities of the BioScope Resolve combined with FluidFM technology opens a broad range of FluidFM applications for BioScope Resolve BioAFM users – from single cell adhesion and injection into single cells, through colloidal studies to nanolithography.

Dr. Pascal Behr, CEO of Cytosurge AG, is very pleased about the new Premium partnership: “Working together with Bruker as one of the world’s leading AFM providers marks an important milestone for Cytosurge. This new Premium partnership reinforces our vision of enabling the full potential of FluidFM technology for the benefit of researchers world-wide. We expect to see many exciting innovations and new applications when our technology is coupled with those of our partners. This new Premium collaboration with Bruker will enable us to deliver highly integrated and versatile FluidFM solutions based on Bruker’s state-of-the-art AFM product portfolio - starting today with the Bruker BioScope Resolve AFM.”

Also David V. Rossi, Executive Vice President and General Manager of Bruker's AFM Business, is satisfied: “Partnering with Cytosurge to integrate FluidFM with BioScope Resolve and PeakForce Tapping technology fits perfectly with our strategy to take BioAFM experiments beyond imaging, from mechanobiology and drug delivery to the probing of biochemical interactions. Manipulating cells, and injecting biomolecules into cells while sensing piconewton forces, and imaging at the nanometer scale, are AFM capabilities that enable fundamentally new correlative information.”

The Partnership with Bruker is the third of a series between Cytosurge and leading AFM manufacturers, designed to make FluidFM available to as many AFM users as possible. Dr. Michael Gabi, CTO of Cytosurge, describes the FluidFM AFM Partnership Program: “We work closely together with established AFM manufacturers to deliver high quality solutions and maximize customer value. Our unique program will allow new and existing AFM owners to leverage their AFM investments to their full potential."

About Bruker Corporation

For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with its customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, phenomics and proteomics research, microbiology and molecular pathology research.

About Cytosurge AG

Founded in 2009, Cytosurge AG successfully develops, manufactures and distributes cutting-edge and unique high-precision nanotechnology instruments as well as robotic systems based on its patented FluidFM® technology.

Cytosurge is focusing its activities into three distinct customer-oriented business units: AFM SOLUTIONS, CELL & BIOSCIENCE and 3DPRINTING, each adapted to its specific target market.

Whether via the FluidFM ADD-ON, a powerful upgrade solution for your AFM, the FluidFM BOT, a fully integrated system for injection into single cells, or via the award-winning FluidFM µ3Dprinter for 3D metal printing at the micrometer scale, Cytosurge provides leading-edge tools and processes to those who need or want to go beyond current technological boundaries.

FluidFM – GO BEYOND.